We are pleased to inform that the company has received the In-principle approval from BSE Limited for Rights issue of Equity Shares, the letter is enclosed
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr Lalchandani Labs Ltd has received in-principle approval from BSE Limited for a proposed Rights Issue of equity shares of face value Rs. 10 each. The company applied on December 15, 2025, and BSE granted approval on January 16, 2026. Key details such as the number of shares, issue price, and premium are still placeholders and have not been disclosed yet. The company must now fix a record date with at least three working days' advance notice and disclose the rights issue price at least three days before the record date. The company remains responsible for all legal, statutory, and disclosure compliances before finalizing the offer documents.
This is an early-stage procedural approval and does not confirm any capital raise yet. Shareholders should watch for the upcoming disclosure of issue price, ratio, and record date, which will determine the dilution impact and cost of subscribing to the rights entitlement.